Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 766 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
PAXMAN Scalp Cooler
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Solid Tumors, Lymphoma
Interventions
Eflapegrastim, Chemotherapy
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Valhalla, New York • Charlotte, North Carolina • Cleveland, Ohio + 1 more
Conditions
Nausea, Vomiting, Anxiety
Interventions
Acupuncture, Aromatherapy
Other
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Englewood, New Jersey
Completed Phase 2 Interventional Results available

ALL Adult Consortium Trial: Adult ALL Trial

NCT00476190
Conditions
Acute Lymphoblastic Leukemia
Interventions
Doxorubicin, Cytarabine, Methotrexate, Vincristine, Cyclophosphamide, Methylprednisone, Hydrocortisone Sodium Succinate, Dexamethasone, 6-MP, PEG-Asparaginase, Imatinib, Etoposide, Radiation Therapy, E. coli Asparaginase
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
7
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Interventions
Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
Procedure · Drug · Biological + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Results available

High-Risk Neuroblastoma Chemotherapy Without G-CSF

NCT02786719
Conditions
Neuroblastoma
Interventions
Topotecan, Cyclophosphamide, Cisplatin, Etoposide, Vincristine, Doxorubicin, Sargramostim
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Months to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
San Diego, California • Houston, Texas
Conditions
Non-Hodgkin's Lymphoma
Interventions
CDOP plus rituximab
Drug
Lead sponsor
Geriatric Oncology Consortium
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Oxnard, California • Washington D.C., District of Columbia • Inverness, Florida + 2 more
Conditions
B-cell Lymphoma, Burkitt Lymphoma
Interventions
Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Dallas, Texas • Madison, Wisconsin • Milwaukee, Wisconsin
Conditions
Lymphoma
Interventions
bleomycin sulfate, filgrastim, ABVD regimen, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
37
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 29 more
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carmustine, cisplatin, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, melphalan, thalidomide, autologous-autologous tandem hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Hartford, Connecticut • Beech Grove, Indiana • Richmond, Indiana + 21 more
Conditions
Multiple Myeloma
Interventions
Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Brain Cancer, Choroid Plexus Tumors
Interventions
Carboplatin, Cisplatin, Cyclophosphamide, Dactinomycin, Doxorubicin, Etoposide, Irinotecan, Leucovorin, Methotrexate, Temozolomide, Vincristine
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
Not listed
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Conditions
Breast Cancer
Interventions
nab-paclitaxel, trastuzumab, Doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
Drug · Biological · Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
2
States / cities
Hays, Kansas • Kansas City, Kansas
Conditions
Lymphoma
Interventions
Aprepitant, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab, Ondansetron
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL, NHL
Interventions
DA-EPOCH, Rituximab, CHOP, Acalabrutinib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 3 Interventional Results available

Docetaxel in Breast Cancer

NCT00312208
Conditions
Breast Cancer
Interventions
Docetaxel,doxorubicin, cyclophosphamide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Mantle Cell Lymphoma
Interventions
Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 79 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions
Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Conditions
Pediatric, Hodgkin's Disease
Interventions
COPP/ABV, intensive chemo with concurrent growth factor
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2008
U.S. locations
1
States / cities
New York, New York
Conditions
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Oral Azacitidine, Positron Emission Tomography, Prednisone, Questionnaire Administration, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
75 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
176
States / cities
Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 136 more
Conditions
Neuroblastoma
Interventions
filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, isotretinoin, melphalan, topotecan hydrochloride, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Memphis, Tennessee + 2 more
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide, Doxorubicin, Prednisone, Pegfilgrastim
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
70 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Multiple Myeloma
Interventions
Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas